EBITDA Margin % is calculated as EBITDA divided by its Revenue. Anika Therapeutics's EBITDA for the
three
months ended in Mar. 2026 was €-3.53 Mil. Anika Therapeutics's Revenue for the
three
months ended in Mar. 2026 was €25.61 Mil. Therefore, Anika Therapeutics's EBITDA margin for the quarter that ended in Mar. 2026 was -13.78%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Anika Therapeutics EBITDA Margin % Related Terms
Anika Therapeutics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Anika Therapeutics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:AKP vs LFCR, DERM, ASRT: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Anika Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anika Therapeutics EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Anika Therapeutics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Anika Therapeutics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anika Therapeutics (STU:AKP) has a EBITDA Margin % of -13.78% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Anika Therapeutics and its competitors. According to the industry distribution chart, Anika Therapeutics ranks #759 out of 952 companies in the Drug Manufacturers industry, placing it in the top 79.7%.
Is Anika Therapeutics' EBITDA Margin % too high?
Anika Therapeutics' current EBITDA Margin % is -13.78%. Based on the distribution chart, Anika Therapeutics ranks #759 out of 952 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Anika Therapeutics has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Anika Therapeutics' EBITDA Margin % compare to LFCR and DERM?
According to the Drug Manufacturers industry distribution chart, Anika Therapeutics ranks #759 out of 952 companies for EBITDA Margin %. This places Anika Therapeutics in the lower half of its industry. The industry median EBITDA Margin % is 12.47. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.47, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Anika Therapeutics and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anika Therapeutics's current EBITDA Margin % is -13.78%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anika Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Anika Therapeutics (STU:AKP) is currently considered Modestly Undervalued. The stock's GF Value™ is €17.79, compared to a current price of €13.10 — trading 26.4% below its estimated fair value. The current EBITDA Margin % is -13.78%. Anika Therapeutics' overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Anika Therapeutics (STU:AKP), the current EBITDA Margin % is -13.78% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Anika Therapeutics (STU:AKP) Overvalued in 2026?
Based on GuruFocus' analysis, Anika Therapeutics stock appears to be undervalued.
The current stock price of €13.10 is trading 26.4% below its estimated GF Value™ of €17.79.
GuruFocus considers Anika Therapeutics to be Modestly Undervalued.
Key valuation signals for STU:AKP:
EBITDA Margin %: -13.78%
GF Value™: €17.79 vs. price of €13.10 (26.4% below fair value)
No single metric tells the full story. See the STU:AKP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
66GF Score
Get the complete analysis for STU:AKP
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:AKP has been successfully added to your 
